

# UCLA

## UCLA Previously Published Works

### Title

Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma

### Permalink

<https://escholarship.org/uc/item/1x73j06v>

### Journal

BMC Cancer, 9(1)

### ISSN

1471-2407

### Authors

Susa, Michiro  
Iyer, Arun K  
Ryu, Keinosuke  
[et al.](#)

### Publication Date

2009-12-01

### DOI

10.1186/1471-2407-9-399

Peer reviewed

Research article

Open Access

# Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma

Michiro Susa<sup>1,2</sup>, Arun K Iyer<sup>3,4</sup>, Keinosuke Ryu<sup>1,2</sup>, Francis J Hornicek<sup>1,2</sup>, Henry Mankin<sup>2</sup>, Mansoor M Amiji<sup>3</sup> and Zhenfeng Duan\*<sup>1,2</sup>

Address: <sup>1</sup>Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA 02114, USA, <sup>2</sup>Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA 02114, USA, <sup>3</sup>Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, MA 02115, USA and <sup>4</sup>Current address: Department of Radiology, Center for Molecular & Functional Imaging, University of California at San Francisco, San Francisco, CA 94107, USA

Email: Michiro Susa - msusa@partners.org; Arun K Iyer - arun.iyer@radiology.ucsf.edu; Keinosuke Ryu - kryu@partners.org; Francis J Hornicek - fhornicek@partners.org; Henry Mankin - hmankin@partners.org; Mansoor M Amiji - m.amiji@neu.edu; Zhenfeng Duan\* - zduan@partners.org

\* Corresponding author

Published: 16 November 2009

Received: 5 May 2009

BMC Cancer 2009, 9:399 doi:10.1186/1471-2407-9-399

Accepted: 16 November 2009

This article is available from: <http://www.biomedcentral.com/1471-2407/9/399>

© 2009 Susa et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## Abstract

**Background:** Drug resistance is a primary hindrance for the efficiency of chemotherapy against osteosarcoma. Although chemotherapy has improved the prognosis of osteosarcoma patients dramatically after introduction of neo-adjuvant therapy in the early 1980's, the outcome has since reached plateau at approximately 70% for 5 year survival. The remaining 30% of the patients eventually develop resistance to multiple types of chemotherapy. In order to overcome both the dose-limiting side effects of conventional chemotherapeutic agents and the therapeutic failure incurred from multidrug resistant (MDR) tumor cells, we explored the possibility of loading doxorubicin onto biocompatible, lipid-modified dextran-based polymeric nanoparticles and evaluated the efficacy.

**Methods:** Doxorubicin was loaded onto a lipid-modified dextran based polymeric nano-system. The effect of various concentrations of doxorubicin alone or nanoparticle loaded doxorubicin on KHOS, KHOS<sub>R2</sub>, U-2OS, and U-2OS<sub>R2</sub> cells was analyzed. Effects on drug retention, immunofluorescence, Pgp expression, and induction of apoptosis were also analyzed.

**Results:** Dextran nanoparticles loaded with doxorubicin had a curative effect on multidrug resistant osteosarcoma cell lines by increasing the amount of drug accumulation in the nucleus via Pgp independent pathway. Nanoparticles loaded with doxorubicin also showed increased apoptosis in osteosarcoma cells as compared with doxorubicin alone.

**Conclusion:** Lipid-modified dextran nanoparticles loaded with doxorubicin showed pronounced anti-proliferative effects against osteosarcoma cell lines. These findings may lead to new treatment options for MDR osteosarcoma.

## Background

Osteosarcoma is the most common primary malignant bone tumor in children and adolescents and accounts for approximately 60% of primary malignant bone tumors diagnosed in the first two decades of life [1]. Standard treatment for osteosarcoma is a combination of surgery and chemotherapy. The cure rate of patients with localized osteosarcoma ranges from 15 to 20% with surgery alone, but improves to approximately 70% when combined with chemotherapy [2]. Unfortunately, for the 40% of patients with progression of osteosarcoma after front-line therapy, further therapy with additional chemotherapy is palliative and toxic. It is estimated that less than 30% of patients with recurrent disease will be cured [2-4].

Cancer cells employ a host of different mechanisms to become resistant to one or more chemotherapeutic agents. It is known that multidrug resistance (MDR) can occur due to the following potential reasons: enhanced detoxification of the drugs through increased metabolism, decrease in drug uptake, a reaction with increased levels of intracellular nucleophiles, enhanced repair of the drug-induced damage to DNA [5], or through overexpression of membrane-bound drug transporter proteins, such as P-glycoprotein (Pgp, ABCB1), multidrug resistance-associated proteins (MRP1, ABCC1 and MRP2, ABCC2) and the breast cancer resistance protein (BCRP, ABCG2) [6]. The development and discovery of agents that reverse MDR with high efficiency and low toxicity has been the focus of extensive research [7-10]. Unfortunately, these compounds are often nonspecific and have low efficiency and/or high toxicity; as such, phase 3 clinical trials of these agents are largely disappointing [7,8,11-14]. Successful management of osteosarcoma would be greatly aided by novel agents that interfere with both intrinsic and acquired mechanisms of drug resistance mechanisms.

To overcome drug resistance and reduce the side effects during chemotherapy, nanotechnology holds promising potential, utilizing targeted drug delivery [15]. Varieties of nanoparticles are available [16]: polymeric nanoparticles, dendrimers, inorganic/metal nanoparticles, quantum dots, liposomes, micelles, and several other types of nano-assemblies. Polymeric nanoparticle based delivery systems offer a significant advantage over other nano-carrier platforms as there is tremendous versatility in choice of polymer matrices that can be used, which allows for the tailoring of nanoparticle properties to meet the specific needs they were intended to meet. Other advantages include ease in surface modification, greater encapsulation efficiency of the payload, payload protection, large surface area-to-volume ratio, and slow or fast polymer erosion for temporal control over the release of drugs [17].

Dextran is a polysaccharide mainly composed of 1,6-linked D-glucopyranose residues. There are several advantages of using dextran as a macromolecular carrier for chemotherapeutic applications because it is biocompatible and inert. Due to its biocompatibility and biodegradability, dextran and its derivatives have been widely used as blood substitutes and drug carriers [18]. Much work has been carried out to realize useful properties for dextran via various chemical modifications for specific applications, especially its use as a polymeric drug carrier [19,20]. Low molecular weight conjugates of dextran have the advantage of reduced side effects, however its therapeutic potential is not optimum, due to its relatively short plasma half-life [21]. Therefore, in this study, we have used high molecular weight dextran-lipid nanoparticles to encapsulate doxorubicin.

Although the drug resistance in osteosarcoma is well known, there is hardly any study that addresses the effect of drug-loaded nanoparticle formulation on drug-resistant osteosarcoma cells. In order to overcome both the dose-limiting side effects of conventional chemotherapeutic agents and the therapeutic failure incurred from MDR tumor cells, we have undertaken the rational design of biocompatible dextran based polymeric nanoparticles for the sustained delivery of doxorubicin.

## Methods

### Chemicals

Dextran (Mw~40 kDa), stearyl amine (99% pure), cystamine, pyridine, sodium periodate (NaIO<sub>4</sub>), sodium cyanoborohydride (NaCNBH<sub>3</sub>), and potassium sulfate (K<sub>2</sub>SO<sub>4</sub>) and azo-bis-isobutyronitrile (AIBN) were obtained from Sigma-Aldrich Chemical Co (St. Louis, MO). Dithiol-modified poly(ethylene glycol) (PEG-(SH)<sub>2</sub>, M.W. 2,000) was purchased from SunBio, Inc. (Seoul, South Korea). Anhydrous lithium chloride (LiCl) was from Fisher Scientific (Philadelphia, PA). Dehydrated dimethylformamide (DMF) and dimethylsulfoxide (DMSO) with molecular sieves was obtained from Acros Organics (Parsippany, NJ). Acryloyl chloride, pyridine and other reagents and solvents were from Sigma-Aldrich and were used as received without further purification.

### Synthesis of lipid-modified dextran polymer

#### Synthesis of dextran acrylate

The synthesis of dextran acrylate was based on the procedure of Zhang et al. [22]. Briefly, a fixed amount of dextran (M.W. ~40 kDa, 2 g) was added to a LiCl/DMF (4% w/v, 50 ml) solvent mixture in a round bottom flask (200 ml). The temperature of the oil bath was raised from room temperature to 120°C over a period of 2 h. The resultant mixture became a homogeneous golden yellow solution. The solution was cooled to room temperature, and pyridine (500 µl) was added and stirred. The reaction mixture

was cooled to 0°C using ice bath and varying amounts of acryloyl chloride (1-1.5 molar excess) was added drop wise using an addition funnel. The reaction was maintained at 0°C until complete addition of acryloyl chloride was done over a period of 1-2 h. The reaction was allowed to continue overnight. The dextran-acrylate obtained was precipitated in excess cold ethanol and washed three times with absolute ethanol. For confirmation of the formation of dextran acrylate, a small portion of the acrylate monomer was polymerized using 0.001% AIBN initiator in DMSO at 60°C for 24 hours, which resulted in formation of the acrylate polymer, confirming the reaction. Alternately, for lipid modification, the dextran-acrylate obtained in step 1 was directly used as the monomer for the next step, in a one-pot synthesis.

#### *Lipid modification of dextran acrylate*

A desired amount (200 mg) of dextran acrylate obtained from above step was dissolved in dry DMF and stirred in a 20 ml glass vial with varying amounts (5-10 mole %) of stearylamine and a catalyst (0.01 mole %  $\text{AlCl}_3$ ). The reaction mixture was heated to 40-50°C in an oil bath for 24 h. The product obtained (stearyl-modified dextran) was precipitated and washed in cold ethanol several times to purify the product. Finally, the lipid-modified dextran derivative was dissolved in small amount of deionized water and lyophilized to yield the pale yellow final product. The stearyl modification of dextran was confirmed by NMR spectroscopy and the % lipid modification was estimated to be 3-7 mole%.

#### **Synthesis of thiolated dextran**

##### *Oxidation of dextran*

The dextran backbone was oxidized based on the procedure of Martwiset et al. [23]. Briefly, a desired amount of  $\text{NaIO}_4$  was dissolved in 60 ml of deionised water. The solution was added to another solution containing 4 g of dextran and 30 ml of de-ionised water. The reaction was stirred in the dark for 2 h at room temperature. At the end of the reaction, the solution was dialyzed using Spectrapor® dialysis membranes (M.W. cutoff 12-14 kDa, Spectrum Labs, Rancho Dominguez, CA) extensively against de-ionized water (2 L) for 4 days with several water replacements. A powdery free-flowing sample was obtained after freeze-drying. Yield: 3.7 g (92.5%).

##### *Thiol modification of dextran*

A 500 mg portion of the oxidized dextran was dissolved in 50 ml pH 5.2 buffer containing  $\text{K}_2\text{SO}_4$  and  $\text{NaCNBH}_3$ . Then, 50 mg of cystamine was added and stirred at 40°C for 4 days. The product was subjected to extensive dialysis and then lyophilized to yield thiolated-dextran. The percent thiolation was quantified by Ellman's reagent [24]. The concentration of sulfohydryl groups in the purified

thiolated dextran derivate was estimated to be  $\sim 14.2 \mu\text{M}/\text{mg}$ .

#### **Preparation of doxorubicin-containing dextran nanoparticles**

A stock solution of 5 mg/ml PEG-(SH)<sub>2</sub>, stearylamine-modified dextran, and thiolated-dextran synthesized above were prepared in deionised water. A 10 mM (1 ml) stock solution of doxorubicin was used for the preparation of doxorubicin loaded nanoparticle. For preparation of mixture, 40  $\mu\text{l}$  of dextran-stearyl amine was first added to a 35  $\mu\text{l}$  (0.35 mM) solution of doxorubicin and mixed well using a vortex shaker. It was then incubated for 5 minutes. To this mixture, 40  $\mu\text{l}$  dextran-thiol derivative was added and incubated for another 5 minutes. Finally, 40  $\mu\text{l}$  of PEG-(SH)<sub>2</sub> was added and incubated for another 15 minutes to form the hydrophilic shell of the nanoparticles. This method of sequential addition was used so that there is better interaction between the hydrophobic groups in doxorubicin and the lipid-modified dextran derivatives. Since the volume of the sample was small, it was gently vortexed and no stirring was used. The doxorubicin efficiency and loading in the nanoparticles was determined by measuring the absorbance of known amount of sample at 485 nm corresponding to  $\lambda$  max of doxorubicin and comparing the values to a standard curve obtained by using a stock solution of doxorubicin.

#### **Particle size and zeta potential measurements**

The particle size and zeta potentials of doxorubicin loaded nanoparticles were performed with the Brookhaven Zeta PALS Instrument (Holtsville, NY). For light scattering experiments, the samples were measured at fixed angle of 90° at 25°C. The scattering intensity was adjusted in the range of 50-500 kcps by diluting the samples with deionised water. For zeta potentials, default parameters of dielectric constant, refractive index, and viscosity of water were used based on the electrophoretic mobility of the nanoparticles.

#### **Cell culture studies**

Human osteosarcoma cell line U-2OS was obtained from the American Type Tissue Collection (Rockville, MD). Dr. Efstathios S. Gonos (National Hellenic research Foundation, Athens, Greece) kindly provided the human osteosarcoma cell line KHOS and the multidrug resistant cell lines KHOS<sub>R2</sub>, U-2OS<sub>R2</sub>. All cell lines were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100  $\mu\text{g}/\text{ml}$  streptomycin (all obtained from Invitrogen, Carlsbad, CA). Cells were incubated at 37°C in 5% CO<sub>2</sub>-95% air atmosphere and passaged when near confluent monolayers were achieved using trypsin-EDTA solution. Resistant cell lines were continuously cultured in 0.1  $\mu\text{M}$  doxorubicin. Doxorubicin

was obtained as unused residual clinical material at the Massachusetts General Hospital (Boston, MA).

#### *Cell culture reagents*

The Pgp1 monoclonal antibody C219 was purchased from Signet (Dedham, MA). The human  $\beta$ -actin monoclonal antibody and the MTT reagents were purchased from Sigma-Aldrich (St. Louis, MO).

#### **Quantitative and qualitative evaluation of doxorubicin uptake in cells**

##### *Flow cytometry*

Cell suspensions of KHOS, KHOS<sub>R2</sub>, U-2OS, and U-2OS<sub>R2</sub> incubated with doxorubicin with or without nanoparticle for 1 hour at 37°C were analyzed for the cellular fluorescence in a FACS Calibur flow cytometer (BD Biosciences, San Jose, CA) with data acquisition using CellQuest software. Doxorubicin is intrinsically fluorescent and can be excited with the 488 nm argon laser light [25]. The cells were washed and resuspended in PBS and fluorescence emission (above 530 nm) and forward angle light scatter were collected, amplified, and scaled to generate histograms. A minimum of 500,000 cells were analyzed for each histogram generated. Final doxorubicin concentration used was 10  $\mu$ M.

##### *Fluorescence microscopy*

Cellular uptake studies were based on the procedure of Venne et al [26]. KHOS and KHOS<sub>R2</sub> cells were seeded at densities of  $5 \times 10^5$  cells/well in 6 well plates and incubated for 24 h to allow cell attachment. Following the incubation, either doxorubicin alone or nanoparticle loaded with doxorubicin was added to each well and were incubated for additional 3 hours. To counterstain nuclei, the cells were incubated with 1  $\mu$ g/ml Hoechst 33342 (Invitrogen, Carlsbad, CA) for 1 minute. After incubation, the cells were washed and resuspended with PBS and were then visualized on a Nikon Eclipse Ti-U fluorescence microscope (Nikon Corp.) equipped with a SPOT RT digital camera (Diagnostic Instruments, Inc., Sterling Heights, MI). Fluorescence intensity and cellular localization was analyzed at a wavelength of 488 nm in triplicate different fields at random.

#### **Cytotoxicity assay**

In vitro cytotoxicity assays were performed by MTT assay as previously described. Briefly,  $3 \times 10^3$  cells per well were plated in 96-well plate during this process. The culture medium used, RPMI 1640, contained increasing concentration of doxorubicin alone or nanoparticle loaded with doxorubicin. After culturing for 5 days, 10  $\mu$ l of MTT (5 mg/ml in PBS) was added to each well and incubated for 3 hr. after dissolving the resulting formazan product with acid isopropanol, the absorbance (A490) was read on a SPECTRA max Microplate Spectrophotometer (Molecular

Devices) at a wavelength of 490 nm. Experiment was performed in triplicate. The IC<sub>50</sub> was defined as the compound or chemo drug concentration required decreasing the A<sub>490</sub> to 50% of the control value.

#### **Western Blot analysis**

Pgp1 was analyzed in total cell lysates. Protein lysates from cells were generated through lysis with  $1 \times$  RIPA Lysis Buffer (Upstate Biotechnology, Charlottesville, VA). The concentration of the protein was determined by Protein Assay reagents (Bio-Rad, Hercules, CA) and a spectrophotometer (Beckman DU-640, Beckman Instruments, Inc., Columbia, MD). 25  $\mu$ g of total protein was processed on Nu-Page 4-12% Bis-Tris Gel (Invitrogen) and transferred to pure nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA). Primary antibodies were incubated in Tris-buffered saline, pH7.4, with 0.1% Tween 20 overnight at 4°C. Signal was generated through incubation with horseradish peroxidase-conjugated secondary antibodies (Bio-Rad, Hercules, CA) incubated in Tris-buffered saline, pH 7.4, with 5% nonfat milk and 0.1% Tween 20 at 1: 2000 dilution for 1 h at room temperature. Positive immunoreactions were detected by using Super Signal® West Pico Chemiluminescent Substrate (Pierce, Rockford, IL).

#### **Cellular apoptosis assay**

Whole-cell lysates were immunoblotted with specific antibodies to PARP (Cell Signaling Technology) and its cleavage products. Positive immunoreactions were detected by using Super Signal® West Pico Chemiluminescent Substrate. Bands were semiquantified by reverse image scanning densitometry with PhotoShop 7.0 (Adobe, San Jose, CA). An area of the gel image that was devoid of signal was assigned to be the background value. Then, each band of the protein representing cleaved PARP from KHOS or KHOS<sub>R2</sub> treated with either doxorubicin alone or nanoparticle loaded with doxorubicin at various concentrations were analyzed for the density beyond background level. To ensure that the loading of the protein was equal and differences were not being observed because of one specimen having more protein than another, the band corresponding to  $\beta$ -actin was determined for each protein. The density of the protein band was normalized to the  $\beta$ -actin band for the protein and the ratio of the cleaved PARP was normalized by dividing by the ratio of the actin corresponding to each cleaved PARP. As a second parameter of apoptotic cell death, we measured caspase-3/7 activity in KHOS and KHOS<sub>R2</sub> after treatment with either doxorubicin alone or nanoparticle loaded with doxorubicin by using Apo-ONE Homogenous caspase-3/7 system according to the manufacturer's instructions (Promega, Madison, WI). The intensity of the emitted fluorescence was determined at a wavelength of 521 nm with

the use of a SPECTRAmax® Microplate Spectrofluorometer (Molecular Devices).

### Statistical analysis

Values shown are representative of triplicate determinations in two or more experiments. Student's t-test was used to compare the differences between groups (GraphPad PRISM® 4 software, GraphPad Software, San Diego, CA). Results are given as mean  $\pm$  SD and results with  $p < 0.05$  were considered statistically significant.

## Results

### Lipid-modified dextran nanoparticles for intracellular doxorubicin delivery

Doxorubicin was incubated with the lipid-modified dextran derivative in deionized water at RT to form nanoparticles by self-assembled hydrophobic interactions. Further a thiolated-dextran derivative and PEGylated-thiol derivative was sequentially mixed with the doxorubicin containing lipid-modified dextran derivated to enhance the binding efficiency of PEG chains to the dextran hydrogel. This method in fact helped in formation of stable nanoparticles with good doxorubicin loading (Figure 1). The mean particle size of the doxorubicin-loaded nanoparticles as determined by dynamic light scattering (DLS) measurement was  $112.4 \pm 4.2$  nm and the zeta potential was almost neutral ( $+1.19 \pm 0.82$  mV). The particles were stable at room temperature and there was not much change in the particle size on storage (for 1 week at  $4^\circ\text{C}$ ).


### Enhancement of intracellular doxorubicin accumulation with nanoparticle delivery

Lipid-modified dextran nanoparticle caused a significant increase in the retention of doxorubicin in both KHOS<sub>R2</sub> (Figure 2A) and U-2OS<sub>R2</sub> (Figure 2B) when examined through flow cytometry. It was potent enough that the fluorescence of drug resistant cells treated with doxorubicin loaded nanoparticles was comparable to that of drug sensitive cells treated with doxorubicin alone.

Using fluorescent microscopy, subcellular distribution of doxorubicin in KHOS and KHOS<sub>R2</sub> was analyzed. After 3 hour incubation with free doxorubicin in drug resistant osteosarcoma cells, the drug was primarily concentrated in the cytoplasm, and a very low level of fluorescence was observed in the nucleus (Figure 3B). When doxorubicin was administered with the nanoparticle to drug resistant cell line, a prominent increase in fluorescence was observed in the nucleus, whereas the fluorescence of the cytoplasm remained virtually unaffected (Figure 3C). This subcellular distribution mimicked that of the drug sensitive variant when treated with doxorubicin (Figure 3A).


### Evaluation of anti-proliferative effects in wild-type and resistance cells

Dextran nanoparticle was non-cytotoxic by itself at a dose utilized in this study (Additional file 1). However, we found that nanoparticles loaded with doxorubicin showed an increased amount of anti-proliferative activity in both drug sensitive and resistant osteosarcoma cell lines in a dose dependent manner (Figure 4A-D). Nanoparticles loaded with doxorubicin showed a 10 fold higher activity compared to doxorubicin alone against U-



**Figure 1**

**Pictorial representation of doxorubicin loaded stearylamine-dextran modified nanoparticles.** The lipid-modified dextran forms hydrophobic association with doxorubicin and the thiol modified dextran interacts with the thiolated/poly(ethylene glycol) (PEG), forming a core shell structure, which is further stabilized by the PEG chains.



**Figure 2**  
**Fluorescence of KHOS, KHOS<sub>R2</sub> (A), U-2OS, and U-2OS<sub>R2</sub> (B) after treatment with doxorubicin alone or nanoparticle loaded with doxorubicin was analyzed by flow cytometry.** The effect of nanoparticle was potent enough that the fluorescence of MDR osteosarcoma cells was comparable to that of drug sensitive variants.

2OS (IC<sub>50</sub> 0.03 μM to 0.3 μM, Figure 4C), 5 fold higher activity against KHOS<sub>R2</sub> (IC<sub>50</sub> 0.6 μM to IC<sub>50</sub> 3 μM, Figure 4B), and 20 fold higher activity against U-2OS<sub>R2</sub> (IC<sub>50</sub> 0.3 μM to 6 μM, Figure 4D).

To estimate the effect of nanoparticle on Pgp expression, we utilized the Western blot assay. Pgp was not expressed in drug sensitive KHOS and U-2OS, however, Pgp was overexpressed in the two drug resistant cell lines KHOS<sub>R2</sub> and U-2OS<sub>R2</sub> (Figure 5). The nanoparticle did not suppress the expression of Pgp, but in contrast, the expression of Pgp gradually increased along with the increase in the concentration of doxorubicin. These effects were observed in two different drug resistant osteosarcoma cell lines (Figure 5).

#### **Induction of cellular apoptosis with doxorubicin nanoparticles**


To assess the efficacy of nanoparticles loaded with doxorubicin to induce apoptosis on KHOS and KHOS<sub>R2</sub>, cleavage of PARP was detected using western blot assay. The dextran nanoparticle itself did not cause cleavage of PARP at a dose utilized in this study (Additional file 2). Although higher concentration of doxorubicin alone

induced apoptosis, nanoparticles loaded with doxorubicin exhibited a much higher apoptosis induction rate in both drug sensitive (Figure 6A, C) and resistant cell lines (Figure 6B, D). In addition, caspase-3/7 activity was significantly increased when KHOS and KHOS<sub>R2</sub> were treated with nanoparticles loaded with doxorubicin (Figure 7A, B).

#### **Discussion**

Osteosarcoma is the most common primary malignant bone tumor among children and adolescents, and although the prognosis has improved dramatically in the last 30 years, a plateau in the survival curve has been reached at approximately 70% for 5-year survival [1,2]. Many studies are undergoing at present including several phase 3 studies to improve the prognosis of patients, but have not resulted in drastic improvements. In this report, a new nanoparticle formulation of co-encapsulated doxorubicin with high potency has been devised and its efficacy against drug resistant osteosarcoma cell lines has been examined.

In the clinical setting, we have always faced the problem of dose limitation, defined as the systemic toxicity of con-



**Figure 3**  
**Subcellular distribution of doxorubicin in drug sensitive and resistant osteosarcoma cell lines was analyzed under fluorescence microscope (A-C).** A prominent increase in fluorescence was observed in the nucleus when multidrug resistant cells were treated with doxorubicin loaded nanoparticles.


ventional chemotherapeutics, an issue that can potentiate the MDR tumor phenotype. A narrow therapeutic index limits the dose that can be applied at any given single treatment, causing an uneven dose of treatment and resulting in some population of tumor cells experiencing low doses of the applied chemotherapeutic agent. This essentially promotes the cells for the development of MDR. Our study demonstrated that nanoparticles loaded with low concentrations of doxorubicin that will be free of cellular damage showed stronger and enhanced antiproliferative activity against both drug sensitive and resistant osteosarcoma cell lines.

In order to develop a biocompatible and safe nanoparticulate system for the delivery of doxorubicin, we chose to synthesize hydrophobically-modified dextran derivatives, which can encapsulate doxorubicin by hydrophobic interactions, similar to the design reported for self-assembled nanosystems [27]. Further a thiolated-dextran derivative and PEGylated-thiol derivative was sequentially mixed with the lipid-modified dextran derivative to enhance the binding efficiency of PEG chains to the dextran hydrogel. PEGylated liposomes and nanoparticles can impart stealth character to the nanoparticles, increase the plasma

residence time, protect the drug payload from degradation during circulation and also passively target tumor tissues due to the leakiness of the neovasculature by the enhanced permeability and retention (EPR) effect [28].

One of the main features of nanoparticles used for drug delivery is their preferable accumulation in solid tumors because of the EPR effect [29]. It has been shown that after administration of nanoparticles without drugs, the EPR effect in solid tumors primarily arose from differences in the clearance rate between solid tumor and normal tissues, after an initial penetration of the polymers into these tissues [30]. This is due to the increased tumor vascular permeability and the poor lymphatic drainage of the tumor tissue. It has been reported that nanoparticle bound drugs is 45-250 times higher in the site of tumors when compared to other organs such as the liver, kidney, lung, spleen, or heart [31]. The actual accumulation inside cells and preservation of drug antitumor activity during its tissue and subcellular trafficking are also important determinants of the efficacy of an anticancer agent. For anthracyclines in MDR cells, it has been reported that, in addition to a decrease in the drug accumulation, the intracellular distribution of the drug is changed in human







**Figure 4**  
**The effect of doxorubicin alone or nanoparticle loaded with doxorubicin on KHOS, KHOS<sub>R2</sub>, U-2OS, and U-2OS<sub>R2</sub> was analyzed (A-D).** Varying concentrations of doxorubicin was added and consequently cultured for 5 days. Nanoparticle loaded with doxorubicin showed increased anti-proliferative activity in both drug sensitive and resistant osteosarcoma cell lines in a dose dependent manner. Growth inhibition was assessed by MTT as described under Methods. The experiment was repeated four times in triplicate.

myeloma [32], myeloid [33], lung tumor cells [34], ovarian carcinoma cells [35], and in epidermoid carcinoma cells [36]. Anthracycline fluorescence was found mainly in the nucleus inside sensitive cells and mainly in the cytoplasm in cells with a relatively high level of resistance [32-34,36]. The question was raised whether this was also applicable to osteosarcoma cell lines. In this study, cellular uptake and intracellular distribution of doxorubicin were examined under fluorescence microscopy. Under immunofluorescence microscope, doxorubicin was primarily accumulated in the nucleus of drug sensitive cells, and in the cytoplasm of drug resistant cells. When doxorubicin was loaded onto nanoparticles and applied to the drug resistant cells, drug distribution mimicked that of sensitive cells. These observations indicate that the nanoparticle formulation is capable of delivering doxorubicin to the nucleus even for the MDR strains. One of the proposed mechanisms that allow nanoparticles to be effective against the MDR cells is their ability to overcome drug


efflux pumps such as Pgp in the cell membrane. In order to assess the effect of doxorubicin loaded nanoparticles on the expression of Pgp, we undertook western blot analysis. Several studies report that drug loaded nanoparticles inhibit *MDR1* genes encoding drug efflux pumps, at the same time downregulating genes responsible for the drug detoxification and nonspecific resistance [37,38]. Interestingly, after 48 hours of incubation with doxorubicin loaded nanoparticle, Pgp was upregulated in the drug resistant cell lines in a dose dependent manner. Recently, several groups have demonstrated that basal expression of *MDR1* is mechanistically controlled at the chromatin level and that the promoter methylation is a dominant epigenetic regulator of *MDR1* transcription [39-42]. It seems that the nanoparticle delivery system caused increased uptake of doxorubicin and distribution in the nucleus that led to specific epigenetic modifications within the *MDR1* region concomitant with *MDR1* upregulation.



**Figure 5**  
**Western blot assay was performed to assess the effect of doxorubicin loaded nanoparticle on expression of Pgp.** The expression of Pgp gradually increased along with the increase in the concentration of doxorubicin on both MDR osteosarcoma cell lines.



**Figure 6**  
**Cleavage of PARP was detected using western blot assay.** Significant increase in apoptosis was observed for drug sensitive (A) and multidrug resistant osteosarcoma cells (B) when they were treated with doxorubicin loaded nanoparticle. Bar graphs represent the result of semiquantification by reverse image scanning densitometry with PhotoShop 7.0 (C, D). *P* values are shown as follows: \**P* < 0.05.



**Figure 7**  
**Caspase-3/7 activity was measured as a second parameter of apoptotic cell death.** KHOS (A) and KHOS<sub>R2</sub> (B) showed significant increase in apoptosis when they were treated with doxorubicin loaded nanoparticle. The experiment was repeated three times in triplicate. P values are shown as follows: \*P < 0.05.

Several *in vitro* studies have suggested that nanoparticle-drug conjugates induce stronger activation of apoptosis-signaling pathways compared with free doxorubicin [37,43]. In contrast, others indicate that cell death induced by the same conjugates occurs primarily by necrosis [44].

In our study, nanoparticles loaded with doxorubicin showed increased apoptosis compared to free doxorubicin, supporting the former results. An additional topic of current investigation is the co-administration of conventional chemotherapy with an efflux pump inhibitor combined with nanoparticles. There have been reports of sequential or concurrent administration of separate Pgp inhibitors and anticancer drugs [45], but this method cannot guarantee the co-action of intended drugs in the same cancer cells due to their different pharmacokinetics and tissue disposition. Introduction of use of nanoparticle based systems could improve the drug uptake and cytotoxicity due to the coexistence of the chemosensitizer, anticancer drugs, and perhaps short nucleic acids such as MDR1siRNA in the same cell, but the precise mechanism of interaction warrants further investigation.

**Conclusion**

Doxorubicin loaded dextran nanoparticle has resulted in a new cancer chemotherapeutic formulation. The indiscriminate ability of the formulation allows it to obliterate both wild type and the MDR osteosarcoma cells *in vitro* by drug accumulation in the nucleus and increased levels of apoptosis.

**Abbreviations**

MDR: multidrug resistance; Pgp: P-glycoprotein; MRP: multidrug resistance-associated protein; BCRP: breast cancer resistance protein; NaO<sub>4</sub>: sodium periodate; NaCNBH<sub>3</sub>: sodium cyanoborohydride; K<sub>2</sub>SO<sub>4</sub>: potassium sulfate; AIBN: azo-bis-isobutyronitrile; PEG-(SH)<sub>2</sub>: dithiol-modified poly(ethylene glycol); LiCl: lithium chloride; DMF: dehydrated dimethylformamide; DMSO: dimethylsulfoxide; DLS: dynamic light scattering; EPR: enhanced permeability and retention.

**Competing interests**

The authors declare that they have no competing interests.

**Authors' contributions**

MS carried out all the studies, analyzed the data, and wrote the first draft of the paper. AKI carried out the synthesis, characterization of the polymeric nanosystems, provided guidance with the study and assisted with the manuscript draft. KR helped in carrying out the experiments. FJH and HM provided experimental reagents and guided the team in the analysis of results and discussions. MMA provided experimental reagents and assisted with the manuscript draft. ZD is the principal investigator who led the research effort, provided guidance with the studies, assisted in data analysis and interpretation, and edited the manuscript. All authors read and approved the final manuscript.

## Additional material

### Additional file 1

The effect of nanoparticle on KHOS and KHOS<sub>R2</sub> was analyzed. The dextran nanoparticle was non-cytotoxic by itself at a dose utilized in this study. The experiment was repeated four times in triplicate.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2407-9-399-S1.PDF>]

### Additional file 2

The effect of nanoparticle on cleavage of PARP was analyzed using western blot assay. The dextran nanoparticle itself did not cause cleavage of PARP on KHOS or KHOS<sub>R2</sub> at a dose utilized in this study.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2407-9-399-S2.PDF>]

## Acknowledgements

This project was supported, in part, by a grant from the National Cancer Institute, NIH (Nanotechnology Platform Partnership), R01-CA119617. Dr. Duan is supported, in part, through a grant from Sarcoma Foundation of America. Support has also been provided by the Gattegno and Wechsler funds.

## References

- Fletcher C, Unni K, Mertens F, eds: *Pathology and Genetics of Tumours of Soft Tissue and Bone* Lyon: IARC Press; 2002.
- Schwartz CL, Gorlick R, Teot L, Krailo M, Chen Z, Goorin A, Grier HE, Bernstein ML, Meyers P, Children's Oncology Group: **Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group.** *J Clin Oncol* 2007, **25(15)**:2057-62.
- Chou AJ, Gorlick R: **Chemotherapy resistance in osteosarcoma: current challenges and future directions.** *Expert Rev Anticancer Ther* 2006, **6(7)**:1075-85.
- Dean M, Fojo T, Bates S: **Tumour stem cells and drug resistance.** *Nat Rev Cancer* 2005, **5**:275-284.
- Mimeault M, Hauke R, Baktra SK: **Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies.** *Clin Pharmacol Ther* 2008, **83(5)**:673-91.
- Lourda M, Trougakos IP, Gonos ES: **Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein J.** *Int J Cancer* 2007, **120(3)**:611-22.
- Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM: **Targeting multidrug resistance in cancer.** *Nat Rev Drug Discov* 2006, **5**:219-234.
- Kaye SB: **Reversal of drug resistance in ovarian cancer: where do we go from here?** *J Clin Oncol* 2008, **26**:2616-2618.
- Sikic BI: **Pharmacologic approaches to reversing multidrug resistance.** *Semin Hematol* 1997, **34**:40-47.
- Shen YC, Chou CJ, Chiou WF, Chen CF: **Anti-inflammatory effects of the partially purified extract of radix Stephaniae tetrandrae: comparative studies of its active principles tetrandrine and fangchinoline on human polymorphonuclear leukocyte functions.** *Mol Pharmacol* 2001, **60**:1083-1090.
- Krishna R, Mayer LD: **Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs.** *Eur J Pharm Sci* 2000, **11**:265-283.
- Twentyman PR, Bleehen NM: **Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected].** *Eur J Cancer* 1991, **27**:1639-1642.
- Kolitz JE, George SL, Dodge RK, Hurd DD, Powell BL, Allen SL, Velez-Garcia E, Moore JO, Shea TC, Hoke E, Caligiuri MA, Vardiman JW, Bloomfield CD, Larson RA: **Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.** *J Clin Oncol* 2004, **22**:4290-4301.
- Sonneveld P, Suci S, Weijermans P, Beksac M, Neuwirtova R, Solbu G, Lokhorst H, Lelie J van der, Dohner H, Gerhartz H, Segeren CM, Willemze R, Lowenberg B: **Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914).** *Br J Haematol* 2001, **115**:895-902.
- Page R, Takimoto C: **Cancer management: a multidisciplinary approach: medical, surgical, and radiation oncology.** In *Principles of chemotherapy* 8th edition. Edited by: Pazdur R. New York: PRP; 2004:21-38.
- Sahoo SK, Labhasetwar V: **Enhanced antiproliferative activity of transferrin- conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention.** *Mol Pharm* 2005, **2**:373-83.
- van Vlerken L E, Vyas T K, Amiji M M: **Poly (ethylene glycol) - modified Nanocarriers for Tumor - targeted and Intracellular Delivery.** *Pharmaceutical research* 2007, **24(8)**:1405-13.
- Hoste K, Bruneel D, De Marre A, De Schrijver F, Schacht E: **Synthesis and characterization of poly(oxyethylene) modified dextrans.** *Macromol Rapid Commun* 1994, **15(9)**:697-704.
- Franssen O, Van Ooijen RD, De Boer D, Maes RAA, Herron JN, Henkin WE: **Enzymatic Degradation of Methacrylated Dextrans.** *Macromolecules* 1997, **30(24)**:7408-13.
- Berrada S, Amedee J, Avramoglou T, Jozefowicz J, Harmand MF: **Effect of a derivatized dextran on human osteoblast growth and phenotype expression.** *J Biomater Sci Polymer Ed* 1995, **6(2)**:211-222.
- Bernstein A, Hurwitz E, Maron R, Arnon R, Sela M, Wilchek M: **Higher antitumor efficacy of daunomycin when linked to dextran: in vivo and in vitro studies.** *J Natl Cancer Inst* 1978, **60(2)**:379-84.
- Zhang Y, Won CY, Chu CC: **Synthesis and characterization of biodegradable network hydrogels having both hydrophobic and hydrophilic components with controlled swelling behavior.** *J Polym Sci Part A: Polym Chem* 2003, **41**:386-394.
- Martwiset S, Koh AE, Chen W: **Nonfouling characteristics of dextran -containing surfaces.** *Langmuir* 2006, **22(19)**:8192-6.
- Ellman GL: **Tissue sulfhydryl groups.** *Arch Biochem Biophys* 1959, **82(1)**:70-7.
- Krishan A, Sauerteig A, Wellham LL: **Flow Cytometric Studies on Modulation of Cellular Adriamycin Retention by Phenothiazines.** *Cancer Res* 1985, **45**:1046-1051.
- Venne A, Li S, Mandeville R, Kabanov A, Alakhov V: **Hypersensitizing Effect of Pluronic L61 on Cytotoxic Activity, Transport, and Subcellular Distribution of Doxorubicin in Multiple Drug-resistant Cells.** *Cancer Res* 1996, **56**:3626-3629.
- Otsuka H, Nagasaki Y, Kataoka K: **PEGylated nanoparticles for biological and pharmaceutical applications.** *Adv Drug Deliv Rev* 2003, **55(3)**:403-19.
- Lukyanov AN, Torchilin VP: **Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs.** *Adv Drug Deliv Rev* 2004, **56(9)**:1273-89.
- Matsumura Y, Maeda H: **A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumor-tropic accumulation of proteins and the antitumor agent SMANCS.** *Cancer Res* 1986, **46**:6387-6392.
- Noguchi Y, Wu J, Duncan R, Strohal J, Ulbrich K, Akaike T, Maeda H: **Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissues.** *Jpn J Cancer Res* 1998, **89**:307-314.
- Minko T, Kopecková P, Kopeček J: **Efficacy of the chemotherapeutic action of HPMA copolymer- bound doxorubicin in a solid tumor model of ovarian carcinoma.** *Int J Cancer* 2000, **86(1)**:108-17.
- Broxterman HJ, Schuurhuis GJ, Lankelma J, Baak JPA, Pinedo HM: **Towards functional screening for multidrug resistant cells in human malignancies.** In *Pezcoller Foundation Symposium. Drug Resistance: Mechanisms and Reversal* Edited by: Mihich E. Rome: John Libbey CIC; 1990:309-319.

33. Hindenburg AA, Baker MA, Gleyzer E, Stewart VJ, Case N, Taub RN: **Effect of verapamil and other agents on the distribution of anthracyclines and on reversal of drug resistance.** *Cancer Res* 1987, **47**:1421-1425.
34. Keizer HG, Schuurhuis GJ, Broxterman HJ, Lankelma J, Schoonen WG, van Rijn J, Pinedo HM, Joenje H: **Correlation of multidrug resistance with decreased drug accumulation, altered sub-cellular drug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells.** *Cancer Res* 1989, **49**:2988-2993.
35. Schuurhuis GJ, Broxterman HJ, Cervantes A, van Heijningen TH, de Lanee JHM, Baak JPA, Pinedo HM, Lankelma J: **Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells.** *J Natl Cancer Inst* 1989, **81**:1887-1892.
36. Willingham MC, Cornwell MM, Cardarelli CO, Gottsmann MM, Pastan I: **Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: Effects of verapamil and other drugs.** *Cancer Res* 1986, **46**:5941-5946.
37. Jiang Z, Chen BA, Xia GH, Wu Q, Zhang Y, Hong TY, Zhang W, Cheng J, Gao F, Liu LJ, Li XM, Wang XM: **The reversal effect of magnetic Fe<sub>3</sub>O<sub>4</sub> nanoparticles loaded with cisplatin on SKOV3/DDP ovarian carcinoma cells.** *Int J Nanomedicine* 2009, **4**:107-114.
38. Chen BA, Dai YY, Wang XM, Zhang RY, Xu WL, Shen HL, Gao F, Sun Q, Deng XJ, Ding JH, Gao C, Sun YY, Cheng J, Wang J, Zhao G, Chen NN: **Synergistic effect of the combination of nanoparticulate Fe<sub>3</sub>O<sub>4</sub> and Au with daunomycin on K562/A02 cells.** *Int J Nanomedicine* 2008, **3**(3):343-50.
39. Kantharidis P, El-Osta A, deSilva M, Wall DM, Hu XF, Slater A, Nadalin G, Parkin JD, Zalcberg JR: **Altered methylation of the human MDR 1 promoter is associated with acquired multidrug resistance.** *Clin Cancer Res* 1997, **3**:2025-2032.
40. Jin S, Scotto KVV: **Transcriptional regulation of the MDR 1 gene by histone acetyltransferase and deacetylase is mediated by NF - Y.** *Mol Cell Biol* 1998, **18**:4377-4384.
41. Nakayama M, Wada M, Harada T, Nagayama J, Kusaba H, Ohshima K, Kozuru M, Komatsu H, Ueda R, Kuwano M: **Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR 1 gene in acute myeloid leukemias.** *Blood* 1998, **92**:4296-4307.
42. El-Osta A, Kantharidis P, Zalcberg JR, Wolffe AP: **Precipitous release of methyl - CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR 1) on activation.** *Mol Cell Biol* 2002, **22**:1844-1857.
43. Duncan R, Kopeckova-Rejmanova P, Strohmalm J, Hume I, Cable HC, Pohl J, Lloyd JB, Kopecek J: **Anticancer agents coupled to [N-(2 hydroxypropyl)methacrylamide] copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro.** *Br J Cancer* 1987, **55**:165-174.
44. Minko T, Kopeckova P, Kopecek J: **Mechanisms of anticancer action of HPMA copolymer-bound doxorubicin.** *Macromol Symp* 2001, **172**:35-37.
45. Miettinen S, Grenmand S, Ylikomia T: **Inhibition of P-glycoprotein-mediated docetaxel efflux sensitizes ovarian cancer cells to concomitant docetaxel and SN-38 exposure.** *Anti-Cancer Drugs* 2009, **20**:267-276.

### Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2407/9/399/prepub>

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

